Sorrento Therapeutics, Inc.
SRNE · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $62,839 | $52,904 | $39,986 | $31,432 |
| % Growth | 18.8% | 32.3% | 27.2% | – |
| Cost of Goods Sold | $33,452 | $13,031 | $9,940 | $12,237 |
| Gross Profit | $29,387 | $39,873 | $30,046 | $19,195 |
| % Margin | 46.8% | 75.4% | 75.1% | 61.1% |
| R&D Expenses | $221,226 | $206,922 | $111,340 | $106,879 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $182,337 | $196,856 | $116,179 | $103,557 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $130,139 | $4,140 | $4,053 | $3,941 |
| Operating Expenses | $533,702 | $407,918 | $231,572 | $214,377 |
| Operating Income | -$504,315 | -$368,045 | -$201,526 | -$195,182 |
| % Margin | -802.6% | -695.7% | -504% | -621% |
| Other Income/Exp. Net | -$57,432 | -$94,483 | -$114,898 | -$100,183 |
| Pre-Tax Income | -$561,747 | -$462,528 | -$316,424 | -$359,576 |
| Tax Expense | -$2,416 | -$33,516 | -$2,014 | -$473 |
| Net Income | -$572,843 | -$429,012 | -$298,461 | -$359,103 |
| % Margin | -911.6% | -810.9% | -746.4% | -1,142.5% |
| EPS | -1.37 | -1.46 | -1.3 | -2.56 |
| % Growth | 6.2% | -12.3% | 49.2% | – |
| EPS Diluted | -1.37 | -1.46 | -1.3 | -2.56 |
| Weighted Avg Shares Out | 419,315 | 294,774 | 229,823 | 140,514 |
| Weighted Avg Shares Out Dil | 419,315 | 294,774 | 229,823 | 140,514 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $24 | $1,091 |
| Interest Expense | $8,574 | $10,224 | $20,181 | $36,139 |
| Depreciation & Amortization | $13,245 | $16,317 | $14,709 | $15,042 |
| EBITDA | -$539,928 | -$435,987 | -$275,690 | -$308,395 |
| % Margin | -859.2% | -824.1% | -689.5% | -981.1% |